Phase II, Open-Label, Randomized, Controlled Study of PM060184 in Advanced, Hormone Receptor Positive, HER2 negative Breast Cancer Patients in Third or Fourth Line Setting.
Phase of Trial: Phase II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs PM 060184 (Primary)
- Indications Breast cancer; Male breast cancer
- Focus Therapeutic Use
- Sponsors PharmaMar
- 18 Nov 2017 Status changed from recruiting to completed.
- 12 Nov 2017 This trial has been completed in Belgium, according to European Clinical Trials Database
- 10 Jun 2017 Biomarkers information updated